Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial). Issue 1 (8th November 2020)

• Record Type: Journal Article
• Authors: Ludwig, Heinz; Hausmann, Bela; Schreder, Martin; Pönisch, Wolfram; Zojer, Niklas; Knop, Stefan; Gunsilius, Eberhard; Egle, Alexander; Petzer, Andreas; Einsele, Hermann; Hajek, Roman; Weisel, Katja; Krenosz, Karl Jochen; Lang, Alois; Lechner, Daniel; Greil, Richard; Berry, David
• Is Part Of: EJHaem. Volume 2:Issue 1(2021)
• Page Start: 99
• Page End: 103
• Publication Date: 2020-11-08
• Subjects: molecular analysis -- mucosal -- multiple myeloma; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.130
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib‐thalidomide‐dexamethasone. Increased alpha diversity (Shannon index) at the phylum level was associated with longer progression‐free survival (PFS) (10.2 vs 8.5 months, P = .04), particularly in patients with very long (>75% quartile) PFS . Additionally, alpha diversity was lower in patients with progressive disease ( P < .05). These findings suggest an interrelationship between the oral microbiome and outcome in patients with MM and encourage a novel direction for diagnostic and/or therapeutic strategies.